Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $9.20.

A number of research analysts have commented on PYXS shares. Stephens started coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an “overweight” rating and a $13.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 target price (down previously from $7.00) on shares of Pyxis Oncology in a report on Friday, December 20th. William Blair downgraded shares of Pyxis Oncology from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 21st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $8.00 price objective (down from $10.00) on shares of Pyxis Oncology in a research note on Friday, December 20th.

Institutional Investors Weigh In On Pyxis Oncology

Institutional investors and hedge funds have recently modified their holdings of the stock. ProShare Advisors LLC purchased a new position in shares of Pyxis Oncology during the fourth quarter valued at about $26,000. Caption Management LLC bought a new stake in Pyxis Oncology during the 4th quarter valued at approximately $35,000. Ameriprise Financial Inc. purchased a new position in shares of Pyxis Oncology during the 4th quarter worth approximately $35,000. Commonwealth Equity Services LLC raised its position in shares of Pyxis Oncology by 61.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 26,250 shares of the company’s stock worth $41,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Graham Capital Management L.P. purchased a new position in shares of Pyxis Oncology in the 4th quarter valued at approximately $47,000. 39.09% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Trading Down 1.6 %

Shares of Pyxis Oncology stock opened at $1.20 on Wednesday. The business’s 50-day moving average price is $1.50 and its 200-day moving average price is $2.66. The firm has a market capitalization of $71.36 million, a PE ratio of -1.17 and a beta of 1.06. Pyxis Oncology has a 12 month low of $1.19 and a 12 month high of $6.85.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.